Trial · NCT02804178
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
NCT02804178, Phase 2, Completed, Millendo Therapeutics, Inc.; results first posted 2021-02-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia. Trials, record NCT02804178. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02804178
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
- NCT number
- NCT02804178
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Millendo Therapeutics, Inc.
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- ATR-101
- First posted
- 2016-06-17
- Last updated
- 2021-03-10
- Results first posted
- 2021-02-17
- Limitations and caveats
- The small number of subjects analyzed as a result of the rarity of the disease (congenital adrenal hyperplasia).and the stage of the study (phase 2a)
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 | Evaluated at baseline and day 15 of each dose level. Each subject will have up to 5 dose levels. | 17-hydroxyprogesterone was measured predose in the morning at the beginning and end of each dose level. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 | Evaluated at baseline and day 15 of each dose level. Each subject will have up to 5 dose levels. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 | ATR-101 | 2 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ATR-101 | 10 | |
| Overall Study | COMPLETED | ATR-101 | 9 | |
| Overall Study | NOT COMPLETED | ATR-101 | 1 |
Source ClinicalTrials.gov
Adverse events34
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Atrioventricular block first degree | Cardiac disorders | ATR-101 | 1 | 10 | 1 |
| other | Abdominal pain upper | Gastrointestinal disorders | ATR-101 | 3 | 10 | 3 |
| other | Diarrhoea | Gastrointestinal disorders | ATR-101 | 3 | 10 | 3 |
| other | Vomiting | Gastrointestinal disorders | ATR-101 | 2 | 10 | 2 |
| other | Dyspepsia | Gastrointestinal disorders | ATR-101 | 1 | 10 | 1 |
| other | Gingival recession | Gastrointestinal disorders | ATR-101 | 1 | 10 | 1 |
| other | Fatigue | General disorders | ATR-101 | 1 | 10 | 1 |
| other | Oedema peripheral | General disorders | ATR-101 | 1 | 10 | 1 |
| other | Nasopharyngitis | Infections and infestations | ATR-101 | 4 | 10 | 4 |
| other | Gastroenteritis viral | Infections and infestations | ATR-101 | 1 | 10 | 1 |
1 to 10 of 34Source ClinicalTrials.gov
See all 34 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ATR-101 | 0 | 10 |
| Total, other adverse events | ATR-101 | 9 | 10 |
| Total, serious adverse events | ATR-101 | 1 | 10 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32589738 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02804178
GET https://conductscience.org/api/trials/v1/NCT02804178/events?page=2